课题基金 / 基金详情

Structure and action of CARDS toxin

Structure and action of CARDS toxin
卡毒素的结构和作用
批准号:
8182002
负责人:
Peter JOHN HART
金额:
$31.66万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2016-06-30

项目摘要

项目成果

Peter JOHN HART的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Asthma is a complex disorder characterized by episodic airway obstruction and hyper-responsiveness, sometimes accompanied by airway remodeling. Although the underlying causes of asthma remain poorly understood, one contributing factor is exposure to respiratory pathogens. For example, asthmatics positive for Mycoplasma pneumoniae (M. pneumoniae) infection have demonstrated an improvement in pulmonary function after antibiotic treatment whereas patients that test negative do not, suggesting a causal relationship between M. pneumoniae infection and asthma symptom severity. Although there is a strong clinical correlation between M. pneumoniae infection and a sub-set of asthma cases, until recently, the identification of a virulence factor that might play a role in disease pathogenesis had remained elusive. This situation changed, however, when we discovered a 591 amino acid protein with ADP-ribosyltransferase (ART) activity in M. pneumoniae designated Community Acquired Respiratory Distress Syndrome ToXin (CARDS TX). The experiments outlined in this proposal are designed to uncover the structure and action of CARDS TX using a range of biophysical techniques. Using the well-established tools of single crystal X-ray diffraction, we will determine: 1) the three-dimensional structure of CARDS TX; 2) CARDS TX in complex with its NAD"" co-factor; 3) CARDS TX in complex with neutralizing monoclonal antibody Fab fragments; and 4) CARDS TX in complex with recombinant extracellular domains of its cell surface receptor surfactant protein-A (SP-A). A longer term goal is to use these 3-D structures in conjunction with the information coming from Projects 1 and 2 as platforms for the design of CARDS TX inhibitors, which may represent novel therapeutic agents for the treatment of asthma and pulmonary inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure-guided redesign of an antischistosomal drug
The Intron Debranching Enzyme (Dbr1) in Amyotrophic Lateral Sclerosis
MOUSE SOD1 AND HUMAN/MOUSE SOD1 CHIMERAS
  • 批准号:
    8361708
  • 项目类别:
  • 资助金额:
    $1.1万
  • 财政年份:
    2011
  • 负责人:
    Peter JOHN HART
  • 依托单位:
Nascent SOD1 in Amyotrophic Lateral Sclerosis